Back to Search Start Over

Robotic Versus Thoracoscopic Minimally Invasive Mitral Valve Surgery: A Systematic Review and Meta-Analysis of Matched Studies.

Authors :
De Jesus J
Estrella J
Jesse J
Binny V
Sri Radhakrishnan Parthasarathy P
Kabir Y
Nallamotu S
Guntupalli SV
Cai LY
Al-Tawil M
Source :
Cardiology in review [Cardiol Rev] 2024 Nov 05. Date of Electronic Publication: 2024 Nov 05.
Publication Year :
2024
Publisher :
Ahead of Print

Abstract

Mitral regurgitation is the most prevalent form of valvular heart disease, impacting over 24 million people globally. Robotic and thoracoscopic minimally invasive mitral valve repair (MIMR) techniques have emerged as viable alternatives to traditional open-heart surgery. However, the comparative effectiveness and safety of these 2 approaches remain underexplored. This systematic review and meta-analysis, conducted according to Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) guidelines, aimed to compare robotic and thoracoscopic MIMR outcomes. A literature search was performed across PubMed, Scopus, and Embase databases to identify studies comparing these 2 surgical techniques. Eligible studies included randomized controlled trials and cohort studies. Six propensity score-matched studies and 1 retrospective cohort study, involving 11,823 patients, were included, with 5851 undergoing robotic mitral valve repair and 5972 receiving thoracoscopic MIMR. No significant differences were found in perioperative mortality [risk ratio (RR): 0.97, 95% confidence interval (CI): 0.65-1.45] or pump/clamp times. Robotic surgery was associated with longer operative times (mean difference: 33.01 minutes) and higher intraoperative transfusion rates (RR: 1.53, 95% CI: 1.07-2.18), but a lower risk of atrial fibrillation (RR: 0.89, 95% CI: 0.83-0.95). In conclusion, robotic and thoracoscopic MIMR show comparable mortality and overall safety profiles. However, robotic surgery may require longer operative times and increased transfusion needs, while reducing the risk of atrial fibrillation. Further high-quality, randomized studies are warranted to validate these findings.<br />Competing Interests: Disclosure: The authors declare no conflict of interest.<br /> (Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)

Details

Language :
English
ISSN :
1538-4683
Database :
MEDLINE
Journal :
Cardiology in review
Publication Type :
Academic Journal
Accession number :
39499089
Full Text :
https://doi.org/10.1097/CRD.0000000000000814